|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Uveitis | |||||
| 2 | More general conditions related to this trial | ||||
| Eye Diseases | |||||
| Uveal Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| Daclizumab | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Sirolimus | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Antibiotics, Antineoplastic | |||||
| Antifungal Agents | |||||
| Antineoplastic Agents | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Eye Institute (NEI) | |||||